GRPR and posterior cortical atrophy: In the same year, a clinical study (Sah et al., 2015) reported the first-in-man study of the 18F-radiolabeled potent synthetic GRPR antagonist 3-cyano-4-18F-fluorobenzoyl-Ala(SO3H)-Ala(SO3H)-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2 (BAY 86-4367), which is used for PET imaging in patients with primary and recurrent PCa.